Liv­ing in its post-Shire world, Take­da con­tin­ues ag­gres­sive li­cens­ing push in $2.3B deal with An­i­ma

As Take­da con­tin­ues chart­ing its post-Shire merg­er course, the Japan­ese drug­mak­er has of­floaded ex­pen­sive chunks of the com­bined busi­ness while tak­ing an ag­gres­sive stance on li­cens­ing deals to place bets on the fu­ture. On Thurs­day, they made an­oth­er one of those bets po­ten­tial­ly to the tune of sev­er­al bil­lion dol­lars.

Take­da has signed a col­lab­o­ra­tion with Is­raeli firm An­i­ma Biotech, cov­er­ing up to six dif­fer­ent pro­grams with promis­es of up to $2.3 bil­lion in mile­stones. Un­der the deal, An­i­ma will ini­tial­ly con­duct pre­clin­i­cal re­search for Hunt­ing­ton’s dis­ease, as well as two oth­er small mol­e­cule can­di­dates.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER